We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

PROMEGA

Promega has a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression,... read more Featured Products: More products

Download Mobile App




Next Generation Sequencing Developed for Monitoring of Mixed Chimerism

By LabMedica International staff writers
Posted on 07 Jan 2021
Hematopoietic stem-cell transplantation (HSCT) is the only curative treatment for patients with hematological malignant and non-malignant diseases. More...
There are more than 50,000 stem cell transplants are carried out annually worldwide and the number is increasing.

Patients undergoing HSCT face at least four different complications such as toxicity related to treatment, infections, recurrence of the underlying malignant disease and immunological reactions including Graft-versus-Host Disease (GVHD). Chimerism analysis is useful to predict threatening relapse, especially when leukemia cell-lineage-specific chimerism analysis is performed.

Clinical immunologists at the Karolinska University Hospital (Stockholm, Sweden) included in a study a total of 651 samples, consisting of 348 artificial samples and 303 clinical samples to evaluate the performance of a novel Next Generation Sequencing (NGS)-based assay (Devyser AB, Stockholm, Sweden) to monitor mixed chimerism (MC) and compare its technical capacity to established techniques for chimerism analysis. Artificial and clinical samples with increasing amounts of patient DNA were compared using real-time PCR detection of indels and SNP, fragment analysis of short-tandem repeats (STR) and NGS analysis of indels.

The team used an in-house STR marker analysis for the chimerism analysis. Additional studies using a commercial STR-based chimerism assay were performed running samples in triplicates with the Powerplex 16 system (Promega Biotech AB, Nacka, Sweden). The Devyser Chimerism NGS kit is based on targeted sequencing of 24 indels and measuring their allele frequency. Each sample is amplified using a single multiplex PCR reaction containing 24 primer pairs to create a target amplicon library (PCR1). In a second PCR reaction (PCR2), sequencing adapters including unique index sequences are introduced into each amplicon, enabling pooling of up to 96 samples in each sequencing run.

The scientists reported that Real-time PCR displayed excellent sensitivity (>0.01%), but poor accuracy (>20 CV% at MC > 20%), while fragment analysis exhibited good accuracy (<5 CV% at MC > 20%) with limited sensitivity (>2.5%). In contrast, NGS chimerism demonstrated a sensitivity (>0.1%) equal to real-time PCR and an accuracy equal or better than STR analysis throughout an extensive range of mixed chimerism (0.1 – 100%). To evaluate performance of the separate techniques for chimerism determination, 75 retrospective patient monitoring samples (3–7 weeks post-HSCT) with low (<5%), intermediate (5–20%) or high mixed chimerism (>20%) were analyzed.

The authors concluded that taken together, the novel NGS-based chimerism assay can replace both STR-based and real-time PCR based assays through improved diagnostic performance and usability. The study was published in the January, 2021 issue of the journal Clinica Chimica Acta.

Related Links:
Karolinska University Hospital
Devyer AB
Promega Biotech AB



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.